Skip to main content
Clinical Trials/NCT00450164
NCT00450164
Completed
Phase 4

Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response.

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau1 site in 1 country50 target enrollmentNovember 2000

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Gastrointestinal Hemorrhage
Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Enrollment
50
Locations
1
Primary Endpoint
Compared efficacy (at least 6 moths of follow-up)
Status
Completed
Last Updated
19 years ago

Overview

Brief Summary

Controlled and randomized study comparing combined treatment (nadolol and endoscopic ligation) versus nadolol associated with isosorbide mononitrate or prazosin according to hemodynamic response, in the prevention of esofagic verices rebleeding.

Detailed Description

The present is a prospective, randomized, open label study, in parallel groups, in which the patients with hemorrhage caused by esofagic varices will be randomized in two groups of treatment, after control of acute hemorrhage. All the patients included will receive standard medical treatment with beta - blockers and endoscopic ligation of the esofagic varices. The control group will be constituted by the patients assigned to receive endoscopic ligation and nadolol (N). The experimental group will be constituted by patients assigned to receive treatment according to the hemodynamic response. All patients included in the experimental group will receive pharmacologic treatment with nadolol combined with Isosorbide Mononitrate (MNI) or Prazosin (PZ). In both groups it will practice a basal hepatic hemodynamic study in the 4th-5th day after their admitance (after achieve hemodynamic stability for at least 48 h and with hemorrhage controlled) and a second control hepatic hemodynamic study 3-4 weeks after the beginning of the pharmacologic treatment, once adjusted doses. In the experimental group, the responders to N + MNI will keep on this treatment, but nonrespondent in the hemodynamic study will switch treatment to N + PZ and a third hepatic hemodynamic study will be performed 3 to 4 weeks after the dosage adjustement. The randomization will be stratified according to the degree of hepatic failure measured by Child-Pugh classification (classes A and B versus C) The design is random to avoid bias in the selection of the patients.

Registry
clinicaltrials.gov
Start Date
November 2000
End Date
June 2004
Last Updated
19 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Eligibility Criteria

Inclusion Criteria

  • Any Patient with endoscopically assessed Variceal Bleeding (esofagic and gastric)
  • Cirrhosis
  • Patient agreement to be included in the study onsentiment signed

Exclusion Criteria

  • Any associated comorbidity with life expectancy lesser than 6 months
  • Patient refusement to be included in the study.
  • Pregnancy
  • Failure to control acute bleeding
  • Previous prophylaxis treatment

Outcomes

Primary Outcomes

Compared efficacy (at least 6 moths of follow-up)

Secondary Outcomes

  • Mortallity
  • Rebleeding

Study Sites (1)

Loading locations...

Similar Trials